LncRNA HOXA‑AS2 promotes the progression of epithelial ovarian cancer via the regulation of miR‑372

Wang,Yanli; Shao,Wenjing

doi:10.3892/ol.2024.14527

LncRNA HOXA‑AS2 promotes the progression of epithelial ovarian cancer via the regulation of miR‑372

Authors:
- Yanli Wang
- Wenjing Shao
View Affiliations

Affiliations: Department of Gynecology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: June 25, 2024 https://doi.org/10.3892/ol.2024.14527
Article Number: 394
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs, such as homeobox A cluster antisense RNA2 (HOXA‑AS2) are understood to be involved in tumor growth and development of numerous cancers. However, the role of HOXA‑AS2 in the progression of human epithelial ovarian cancer (EOC) remains unclear. In the present study, the expression of HOXA‑AS2 was found to be upregulated in EOC tissues compared with noncancerous tissues, and to be strongly correlated to an advanced Federation International of Gynecology and Obstetrics grade and poor prognosis. Knockdown of HOXA‑AS2 in the EOC cells inhibited cell proliferation, invasion and migration, as well as inducing cell apoptosis. The ENCORI database was used to screen the microRNAs (miRNAs/miRs) that bound to HOXA‑AS2, and one was tested using RNA pull‑down and luciferase reporter assays. It was demonstrated that HOXA‑AS2 functioned through the competing endogenous RNA mechanism to regulate miR‑372. It was also demonstrated that the downregulation of miR‑372 reversed the inhibitory effects of the knockdown of HOXA‑AS2 in EOC cells. These results indicated that HOXA‑AS2 promoted EOC progression by regulating the miR‑372, which suggests that HOXA‑AS2 may be a therapy target for EOC.

View Figures

View References

1	Sambasivan S: Epithelial ovarian cancer: Review article. Cancer Treat Res Commun. 33:1006292022. View Article : Google Scholar : PubMed/NCBI
2	Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019. View Article : Google Scholar : PubMed/NCBI
3	Nougaret S, McCague C, Tibermacine H, Vargas HA, Rizzo S and Sala E: Radiomics and radiogenomics in ovarian cancer: A literature review. Abdom Radiol (NY). 46:2308–2322. 2021. View Article : Google Scholar : PubMed/NCBI
4	Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, Tempst P, Rosenfeld MG, Glass CK and Kurokawa R: Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 454:126–130. 2008. View Article : Google Scholar : PubMed/NCBI
5	Cech TR and Steitz JA: The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 157:77–94. 2014. View Article : Google Scholar : PubMed/NCBI
6	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sun T: Long noncoding RNAs act as regulators of autophagy in cancer. Pharmacol Res. 129:151–155. 2018. View Article : Google Scholar : PubMed/NCBI
8	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
9	Braga EA, Fridman MV, Moscovtsev AA, Filippova EA, Dmitriev AA and Kushlinskii NE: LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms. Int J Mol Sci. 21:88552020. View Article : Google Scholar : PubMed/NCBI
10	Wang JY, Lu AQ and Chen LJ: LncRNAs in ovarian cancer. Clin Chim Acta. 490:17–27. 2019. View Article : Google Scholar : PubMed/NCBI
11	Yang Z, Zhang F, Cai K and Xu J: LncRNA HOXA-AS2 facilitates prostate cancer progression by inhibiting miR-885-5p to upregulate KDM5B. Kidney Blood Press Res. 48:45–55. 2023. View Article : Google Scholar : PubMed/NCBI
12	Wang F, Wu D, Chen J, Chen S, He F, Fu H, Wu Q, Liu S, Li X and Wang W: Long non-coding RNA HOXA-AS2 promotes the migration, invasion and stemness of bladder cancer via regulating miR-125b/Smad2 axis. Exp Cell Res. 375:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
13	Jiang L, Wu Z, Meng X, Chu X, Huang H and Xu C: LncRNA HOXA-AS2 facilitates tumorigenesis and progression of papillary thyroid cancer by modulating the miR-15a-5p/HOXA3 Axis. Hum Gene Ther. 30:618–631. 2019. View Article : Google Scholar : PubMed/NCBI
14	Ding J, Xie M, Lian Y, Zhu Y, Peng P, Wang J, Wang L and Wang K: Long noncoding RNA HOXA-AS2 represses P21 and KLF2 expression transcription by binding with EZH2, LSD1 in colorectal cancer. Oncogenesis. 6:e2882017. View Article : Google Scholar : PubMed/NCBI
15	Wu J, Li M and Zhang Y: Long noncoding RNA HOXA-AS2 regulates the expression of SCN3A by sponging miR-106a in breast cancer. J Cell Biochem. 120:14465–14475. 2019. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Xu J, Zhang S, An J, Zhang J, Huang J and Jin Y: HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma. Cell Physiol Biochem. 50:2124–2138. 2018. View Article : Google Scholar : PubMed/NCBI
17	Lian Y, Li Z, Fan Y, Huang Q, Chen J, Liu W, Xiao C and Xu H: The lncRNA-HOXA-AS2/EZH2/LSD1 oncogene complex promotes cell proliferation in pancreatic cancer. Am J Transl Res. 9:5496–5506. 2017.PubMed/NCBI
18	Guan X, Zong ZH, Chen S, Sang XB, Wu DD, Wang LL, Liu Y and Zhao Y: The role of miR-372 in ovarian carcinoma cell proliferation. Gene. 624:14–20. 2017. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z and Falanga V: Research techniques made simple: Analysis of collective cell migration using the wound healing assay. J Invest Dermatol. 137:e11–e16. 2017. View Article : Google Scholar : PubMed/NCBI
21	Huang X, Huang M, Kong L and Li Y: miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma. Cell Prolif. 48:593–599. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li Y, Li F, Feng C, Wu T, Chen Y, Shah JA, Wang F, Cai Y, Wang J and Jin J: MiR-372-3p functions as a tumor suppressor in colon cancer by targeting MAP3K2. Front Genet. 13:8362562022. View Article : Google Scholar : PubMed/NCBI
23	Chan JJ and Tay Y: Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci. 19:13102018. View Article : Google Scholar : PubMed/NCBI
24	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Yang B, She Y and Ye Y: The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 119:7790–7799. 2018. View Article : Google Scholar : PubMed/NCBI
26	Fang W and Xia Y: LncRNA HLA-F-AS1 attenuates the ovarian cancer development by targeting miR-21-3p/PEG3 axis. Anticancer Drugs. 33:671–681. 2022. View Article : Google Scholar : PubMed/NCBI
27	Zheng ZJ, Liu Y, Wang HJ, Pang WW and Wang Y: LncRNA SNHG17 promotes proliferation and invasion of ovarian cancer cells through up-regulating FOXA1. Eur Rev Med Pharmacol Sci. 24:9282–9289. 2020.PubMed/NCBI
28	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
29	Kasinski AL and Slack FJ: Epigenetics and genetics MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
30	Di Leva G and Croce CM: The role of microRNAs in the tumori-genesis of ovarian cancer. Front Oncol. 3:1532013. View Article : Google Scholar : PubMed/NCBI
31	Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, Wood W III, Becker KG and Morin PJ: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 3:e24362008. View Article : Google Scholar : PubMed/NCBI
32	Chen R and He P: Long noncoding RNA HOXA-AS2 accelerates cervical cancer by the miR-509-3p/BTN3A1 axis. J Pharm Pharmacol. 73:1387–1396. 2021. View Article : Google Scholar : PubMed/NCBI